UBX Unity Bio Gross Return on Sales

UBX (Unity Biotechnology Inc.) - company brandmark

Unity Biotechnology develops senolytics to combat ocular pathologies amidst a fierce patent race. The stability of the gross margin on this chart allows for the filtering of market noise to reveal the actual profitability vector. The value of 0.00 indicates the level of this metric. Strict clinical barriers ensure the protection of developments, while data analysis efficiency is enhanced through the implementation of robotic molecule screening.

Gross Profitability: unitybiotechnology.com (UBX) for 07/04/2022 - 07/19/2025

Financial and market metric breakdowns for Unity Biotechnology, Inc (UBX)

Summary company analysis:UBX Unity Bio
Signature product of Unity Bio

Unity Biotechnology specializes in developing senolytic drugs for the therapy of age-related joint and vision pathologies. Gross margin quantifies the efficiency of this model by deducting direct production costs from revenues, including future licensing royalties. This indicator determines the portion of revenue available to cover operating expenses; therefore, growth in the aggregate gross margin confirms a fundamental strengthening of the business's profitability.

Key competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|Gross Profitability Boundless Bio Inc.|Return on Gross Profit Exicure (XCUR)|Gross Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Gross Profit Rate|Mustang Bio, Inc. - Return on Gross Profit|RNAZ - Return on Gross Profit|BNGO: Return on Gross Profit|APDN (Applied DNA Sciences Inc) - Gross Return on Sales|BLUE (Bluebird Bio) - Return on Gross Profit|ImmunoPrecise Antibodies Ltd - Gross Profit Rate|OMGA (Omega Therapeutics Inc) - Gross Margin|Gross Profitability OMIC|Gross Profitability Regulus Therapeutics Inc. (RGLS)|Return on Gross Profit Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Return on Gross Profit|Gross Profit Rate TCON